SUPRAJA ATHERIYA

SUPRAJA ATHERIYA

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
SASUPRAJA ATHERIYA
SUPRAJA ATHERIYA
GRGundawar Ravi
Gundawar Ravi
TPTanvi Painginkar
Tanvi Painginkar
GKGirish Pai K.
Girish Pai K.
VLVirendra Ligade
Virendra Ligade
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
Chronic Obstructive Pulmonary Disorder (COPD) is a diverse lung ailment characterized by persistent respiratory symptoms such as coughing, dyspnea, sputum formation, and worsening that causes increased airflow limitation. Globally, COPD ranks third in 2019 and is responsible for 3.23 million deaths. It is a health problem that is brought on by inflammation in the lungs. The respiratory system comprises the trachea, bronchi, larynx, paranasal sinuses, and two lungs. COPD and other Respiratory Disorders (RDs) have dominated research. This review emphasizes the potential of novel treatment strategies for COPD, highlighting advanced therapeutic approaches. It addresses the ongoing challenges associated with the effective delivery of pharmaceuticals to targeted sites while aiming to achieve optimal therapeutic outcomes with reduced dosages. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report 2024 categorizes COPD treatments into pharmacological and non-pharmacological interventions. Pharmacological therapies aim to alleviate symptoms, enhance exercise tolerance, reduce exacerbations, and improve health outcomes. These include antibiotics, Long-Acting Beta-Agonist (LABA), Short-Acting Beta-Agonist (SABA), Long-Acting Muscarinic-Antagonists (LAMA), Short-Acting Muscarinic-Antagonists (SAMA), Inhaled Corticosteroids (ICS), and bronchodilators in various formulations. The report also reviews inhaler types and highlights the role of nanoscale drug delivery systems in detecting drug particle deposition in the respiratory tract, along with the characterization and classification of Nanoparticles (NPs) in nanomedicine. In conclusion, contemporary nanoparticles enhance biodistribution, optimize pharmacokinetics, and promote physiological stimulation. They also reduce toxicity and increase the therapeutic index, thereby facilitating the transformation of medication administration for chronic respiratory disorders.

9 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
VCVikas Chandnani
Vikas Chandnani
STSanjay Tiwari
Sanjay Tiwari
MBManoj Bob
Manoj Bob
APAmol Pawar
Amol Pawar
SKSuhas Khandave
Suhas Khandave
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
Precise quantitative determination of Vascular Endothelial Growth Factor (VEGF) in human plasma is critical for pharmacodynamic (PD) evaluation of anti-VEGF therapeutics. In this study, we developed and optimized two immunoassay platforms, including the enzyme-linked immunosorbent assay (ELISA) and the Meso Scale Discovery (MSD), for estimating VEGF. A direct sandwich ELISA was validated to quantify pharmacodynamic biomarker VEGF in human plasma using the Human VEGF Quantikine Kit, demonstrating a quantification range of 62.5–2000.0 pg/mL and a sensitivity of 47.5 pg/mL. In parallel, a sandwich electrochemiluminescence (ECL) assay was developed using the V-PLEX Plus Human VEGF Kit on the MSD platform, achieving a lower quantification range of 7.7–562.0 pg/mL. Comparative analysis revealed that MSD ECL detection with Sulfo Tag labeling outperformed traditional colorimetric ELISA in terms of signal amplification and dynamic range, making it a valuable tool for PD biomarker analysis. Findings underscore the importance of early platform selection to ensure robust, fit-for-purpose biomarker quantification for clinical pharmacology studies and regulatory submissions.

29 January 2026 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
VCVikas Chandnani
Vikas Chandnani
STSanjay Tiwari
Sanjay Tiwari
MBManoj Bob
Manoj Bob
SVS.G. Vasantharaju
S.G. Vasantharaju
GRGundawar Ravi
Gundawar Ravi
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
Bevacizumab (BVZ) is an anti-vascular Endothelial Growth Factor-A monoclonal antibody (mAb) widely used in oncology and ophthalmology indications globally. Accurate quantification of mAbs in biological fluids is an essential prerequisite for determining pharmacokinetic (PK) parameters to assess the relationship between drug exposure and response. We developed and evaluated PK assays for BVZ in human serum using enzyme-linked immunosorbent assays (ELISA) and Meso Scale Discovery (MSD) immunoassay platforms to assess sensitivity and performance. The ELISA method, employing a Streptavidin-Biotin detection system with anti-idiotypic antibodies, demonstrated five times greater sensitivity than the conventional horseradish peroxidase-based ELISA format. The validated PK bridging ELISA achieved a quantification range of 10–220 ng/mL, extendable to 5000 ng/mL via dilution. In contrast, the MSD assay utilized electrochemiluminescence detection with Sulfo Tag labeling, offering a 20-fold higher sensitivity and detecting BVZ at concentrations as low as 500 pg/mL. This parallel evaluation concluded that ELISA is suitable for routine PK analysis due to its robustness and cost-efficiency. At the same time, MSD is advantageous for detecting BVZ at low concentrations in early-phase clinical trials and ophthalmic applications where serum levels are minimal.

13 October 2026 in Bioanalysis
Verified
Journal Article
Closed access
VCVikas Chandnani
Vikas Chandnani
STSanjay Tiwari
Sanjay Tiwari
MBManoj Bob
Manoj Bob
APAmol Pawar
Amol Pawar
SKSuhas Khandave
Suhas Khandave
MSMuddukrishna badamane sathyanarayana
Muddukrishna badamane sathyanarayana
1. Biologic medicines have transformed the therapeutic landscape for many chronic and severe diseases by enabling highly specific targeting of disease pathways. Biologic products encompass a broad ...